Loading…
← CockpitCompetitor Analysis › 6472.TW Bora Pharmaceuticals Co LtdOpen in the cockpit ↗

Bora Pharmaceuticals Co Ltd6472.TWCompetitor analysis, valuation and peers

Taiwan · TWD·Health Care›Pharmaceuticals: Other

Contract development and manufacturing organization (CDMO) for pharmaceuticals, with plants in Taiwan and North America.

≈ A small-cap CatalentMomentum neutral 51
Mkt cap
$1.25B
US dollars, full cap
Free float
55%
of shares outstanding
$/day
$10.6M
20-day average traded
Fwd P/E
10.8×
forward earnings
ROIC−WACC
+1.0 pp
WACC 5.0%
Hurdle
-57 pp
Req g minus delivered
Next earnings
112 days
10 Mar 2027
Close · TWDNT$344.50
1D-2.8%
1W-14.5%
1M-19.0%
3M-15.8%
6M-2.4%
YTD-29.4%
1Y-43.8%
ATR %5.8%
52w lowhigh47.1% off high

What Bora Pharmaceuticals does

Contract development and manufacturing organization (CDMO) for pharmaceuticals, with plants in Taiwan and North America.

Paid by drugmakers under development and manufacturing contracts, so revenue rests on a limited number of multi-year client relationships. Its North American plants, bought from other drug companies, put capacity close to US customers.

In one line: A small-cap Catalent.

Products and services

  • Oral solid dose manufacturing
  • Sterile/injectable manufacturing
  • Formulation development

Customers

  • Pharma/biotech companies outsourcing manufacturing

Where it sits in the supply chain

  • Health Care
  • Pharma services
  • CDMO (contract manufacturing)

What could go right

  • Pharma outsourcing trend
  • North American plant acquisitions adding capacity

What could go wrong

  • Customer concentration risk
  • Capex-heavy plant integration

Moat: narrow (regulatory licence, switching costs, process know-how). FDA-approved plants and multi-year manufacturing contracts are costly for clients to re-qualify.

Headquarters: Taipei, Taiwan

Named competitors

Bora Pharmaceuticals at a glance

Size Bora Pharmaceuticals (6472.TW) is a Taiwan Health Care company (Pharmaceuticals: Other) with a market value of $1.25B, the 225th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$344.50 on 18 Nov 2026.

Performance Over six months the shares fell 2.4%, against -9.8% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 8th highest of 21 in its peer set.

Growth Revenue grew 6.5% over the last twelve months (peer median +9.1%); the operating margin is 14.3% (peer median 15.9%).

Valuation It trades at 10.8× forward earnings against a peer median of 20.6× (4th cheapest of 18).

Price implies For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +60%, so the hurdle is -57 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 1.0 points above its cost of capital (5.0% WACC).

Next results Next results expected around 10 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026Peer median 926472.TW 89
Six months, rebased to 100: Bora Pharmaceuticals against the median of its 20 peers (local-currency closes).

Bora Pharmaceuticals financials

Reported figures in TWD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueNT$21.2BNT$19.0BNT$17.4BNT$14.2BNT$10.5B
Revenue growth—+9%+23%+35%—
Gross profitNT$7.91BNT$7.66BNT$7.63BNT$6.91BNT$2.86B
EBITDANT$4.32BNT$4.23BNT$4.56BNT$5.85BNT$2.25B
Net incomeNT$1.53BNT$2.98BNT$3.85BNT$3.03BNT$1.39B
Free cash flowNT$2.42BNT$3.31BNT$83.0MNT$4.16BNT$1.72B
Capital expenditureNT$2.04BNT$1.01BNT$856MNT$1.43BNT$215M
Total debtNT$25.7BNT$18.2BNT$19.0BNT$5.01BNT$7.60B

Quarterly statements and history in the cockpit →

Bora Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%0%+20%BIOG-BPHMJWELCRON2142SUDEEPPHRM0022756002160719APN300363002219PHN04606032622877300791GRANULES6472.TW6-month return →1-month return →
Up and to the right = strong over both horizons. Bora Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%+60%0×100×BIOG-BPHMJWELCRON2142SUDEEPPHRM002275600216APN00221904606032622877GRANULES6472.TWRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Bora Pharmaceuticals is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%20%40%60%BIOG-BPHMJWELCRON21420022756002160719APNPHN603262600056300791GRANULES6472.TWGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Bora Pharmaceuticals is the large dot.

Bora Pharmaceuticals competitors and peer comparison

Head to head with its named competitors (6472.TW vs LONN.SW vs SFZN.SW vs 6446.TW)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Bora Pharmaceuticals 6472.TW$1.25B-2%+7%14%10.8×3.5%
Lonza LONN.SW$53.9B+36%-11%25%36.1×15.6%
Siegfried SFZN.SW$3.51B-17%+4%16%16.8×n/a
PharmaEssentia 6446.TW$15.0B+67%+78%40%31.9×23.7%

How Bora Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Bora Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
Measure6472.TWPeer medianRank in peer set
1-month return-19.0%-2.3%lowest of 21
6-month return-2.4%-9.8%8th highest of 21
Distance from 52-week high-47.1%-29.8%3rd lowest of 21
Revenue growth (TTM)+6.5%+9.1%11th highest of 21
Operating margin14.3%15.9%10th lowest of 21
Forward P/E10.8×20.6×4th cheapest of 18
Growth the price implies (Req g, 7 yrs)3.5%7.7%8th least demanding of 17
Growth delivered (Del g)+60.2%+12.0%2nd highest of 17
Hurdle (Req g minus delivered)-56.8 pp-8.8 ppleast demanding of 17
ROIC minus cost of capital+1.0 pp+2.7 pp8th lowest of 21
EV / EBITDA14.7×18.2×4th cheapest of 11
Net debt / EBITDA4.6×-1.1×most indebted of 12

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Bora Pharmaceuticals 6472.TWTaiwan$1.25B-2%+7%14%10.8×3.5%+60.2%
BioGaia BIOG-B.STSweden$1.25B-4%+13%28%31.0×1.5%+15.5%
Pharma Mar PHM.MCSpain$1.21B-38%+32%19%41.4×10.6%-3.9%
Jamieson Wellness JWEL.TOCanada$1.32B+32%+12%13%20.6×13.5%+15.3%
Cronos CRON.TOCanada$1.17B+24%+55%5%16.2×18.8%+26.7%
HBM 2142.HKHong Kong$1.12B-18%+55%44%11.7×13.1%+62.3%
Sudeep Pharma SUDEEPPHRM.NSIndia$1.45B+85%+27%33%69.1×n/an/a
Guilin Sanjin Pharmaceutical 002275.SZChina$1.05B-12%-3%24%12.8×-8.7%+5.5%
Zhejiang Medicine 600216.SSChina$1.51B-26%-6%7%11.5×-7.8%+3.9%
Shandong Xinhua Pharmaceutical 0719.HKHong Kong$1.03B-19%-1%4%6.2×-2.1%+7.1%
Tibet Cheezheng Tibetan Medicine 002287.SZChina$1.58B-17%-7%28%n/a-1.9%+10.4%
Applied Nutrition APN.LUnited Kingdom$986M+31%+51%25%21.4×24.6%+38.5%
Porton Pharma Solutions 300363.SZChina$1.66B+37%+6%-2%n/a2.1%+10.4%
New Journey Health Technology Group Co., Ltd.Class A 002219.SZChina$942M-18%-14%8%182.0×n/an/a
PharmaNutra PHN.MIItaly$922M+2%+17%22%33.5×4.7%+18.5%
Sihuan Pharmaceutical 0460.HKHong Kong$856M-34%+30%15%8.7×n/an/a
TSI 603262.SSChina$842M-46%+3%14%47.7×24.3%+13.4%
China Meheco 600056.SSChina$1.90B-16%+2%3%n/a-1.3%-2.1%
China Shineway Pharmaceutical 2877.HKHong Kong$760M-8%-18%25%7.6×n/an/a
Sirio Pharma 300791.SZChina$759M-6%-9%1%16.2×14.1%+15.6%
Granules India GRANULES.NSIndia$2.12B+4%+22%17%24.8×23.6%+10.6%

Questions

Who are Bora Pharmaceuticals's main competitors?
Named competitors: Catalent (private or unlisted), Lonza (LONN.SW), Siegfried Holding (SFZN.SW), PharmaEssentia (6446.TW). The cockpit's measured peer set (industry) also includes BioGaia (BIOG-B.ST), Pharma Mar (PHM.MC), Jamieson Wellness (JWEL.TO), Cronos (CRON.TO), HBM (2142.HK), Sudeep Pharma (SUDEEPPHRM.NS).
Is Bora Pharmaceuticals expensive compared with its peers?
On forward p/e it trades at 10.8× against a peer median of 20.6×, 4th cheapest of 18 in its peer set. For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +60%, so the hurdle is -57 pp: the price already allows for a slowdown.
How has Bora Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned -2.4% against -9.8% for the median peer; over one year -43.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.